AbbVie (ABBV) Net Income Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
131.31% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
109.43% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
5.72% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
109.43% |
| Dec 31, 2025 |
-9.79% |
| Sep 30, 2025 |
-63.77% |
| Jun 30, 2025 |
0.46% |
| Mar 31, 2025 |
-34.05% |
| Dec 31, 2024 |
-26.11% |
| Sep 30, 2024 |
-21.06% |
| Jun 30, 2024 |
21.32% |
| Mar 31, 2024 |
-27.19% |
| Dec 31, 2023 |
178.86% |
| Sep 30, 2023 |
-8.34% |
| Jun 30, 2023 |
68.01% |
| Mar 31, 2023 |
-26.67% |
| Dec 31, 2022 |
-4.08% |
| Sep 30, 2022 |
28.01% |
| Jun 30, 2022 |
7.79% |
| Mar 31, 2022 |
22.30% |
| Dec 31, 2021 |
61.54% |
| Sep 30, 2021 |
5.00% |
| Jun 30, 2021 |
-27.08% |
| Mar 31, 2021 |
8.50% |
| Dec 31, 2020 |
-9.93% |
| Sep 30, 2020 |
12.35% |
| Jun 30, 2020 |
-33.62% |
| Mar 31, 2020 |
20.72% |
| Dec 31, 2019 |
26.28% |
| Sep 30, 2019 |
5.64% |
| Jun 30, 2019 |
-22.79% |
| Mar 31, 2019 |
21.96% |
| Dec 31, 2018 |
-47.42% |
| Sep 30, 2018 |
30.40% |
| Jun 30, 2018 |
13.23% |
| Mar 31, 2018 |
39.64% |
| Dec 31, 2017 |
27.33% |
| Sep 30, 2017 |
47.72% |
| Jun 30, 2017 |
20.37% |
| Mar 31, 2017 |
20.41% |
| Dec 31, 2016 |
-7.40% |
| Sep 30, 2016 |
18.35% |
| Jun 30, 2016 |
14.66% |
| Mar 31, 2016 |
11.84% |
| Dec 31, 2015 |
-2.64% |
| Sep 30, 2015 |
-7.88% |
| Jun 30, 2015 |
2.54% |
| Mar 31, 2015 |
4.99% |